Back to results
US 12,655,128 B2Granted
Inhibitors of ret
AssigneeRigel Pharmaceuticals, Inc.
InventorsJason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions. In certain embodiments, the compounds have Formula IIa or IIb:
Claims12
A compound having the structural formula (IIb):
- or a pharmaceutically acceptable salt thereof, wherein:
- X1 is selected from N, CH and C (halo);
- X2 is selected from N and CH;
- X3 is selected from N and CH;
- R12 is selected from hydrogen, hydroxyl, halo and O—C1-C4 alkyl;
- each of R13a, R13b, R18a and R18b is independently selected from hydrogen and C1-C4 alkyl;
- R14 is selected from hydrogen, —C1-C4 alkyl and —O—C1-C4 alkyl;
- R15 is selected from hydrogen and —C1-C4 alkyl;
- R16 is selected from hydrogen and —C1-C4 alkyl;
- R17b is selected from hydrogen and halo;
- and
- R17a and R17c are independently selected from hydrogen and —C1-C4 alkyl.
9 more elements
Dependencies are inferred from the claim text.